 Shankar Munusamy
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Nephropathies | 6 | 2023 | 301 | 2.450 |
Why?
| | Education, Pharmacy | 6 | 2025 | 127 | 2.120 |
Why?
| | Students, Pharmacy | 3 | 2025 | 100 | 1.740 |
Why?
| | Kidney Tubules, Proximal | 4 | 2019 | 132 | 1.470 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2019 | 198 | 1.290 |
Why?
| | Metformin | 3 | 2019 | 334 | 1.240 |
Why?
| | Endoplasmic Reticulum Stress | 6 | 2018 | 117 | 1.110 |
Why?
| | Aldehyde Reductase | 2 | 2017 | 31 | 1.040 |
Why?
| | Pharmacology | 1 | 2025 | 11 | 0.950 |
Why?
| | Resilience, Psychological | 1 | 2025 | 127 | 0.790 |
Why?
| | Mindfulness | 1 | 2025 | 145 | 0.760 |
Why?
| | Glucose | 4 | 2021 | 1032 | 0.730 |
Why?
| | Diabetes Complications | 2 | 2019 | 226 | 0.620 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2018 | 201 | 0.610 |
Why?
| | Health Promotion | 1 | 2025 | 745 | 0.580 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2513 | 0.570 |
Why?
| | Mitochondria | 4 | 2015 | 958 | 0.570 |
Why?
| | Education, Distance | 1 | 2018 | 53 | 0.560 |
Why?
| | Pyruvaldehyde | 1 | 2018 | 47 | 0.540 |
Why?
| | Kidney | 6 | 2021 | 1480 | 0.540 |
Why?
| | Polyunsaturated Alkamides | 1 | 2017 | 10 | 0.530 |
Why?
| | Rhodanine | 1 | 2017 | 2 | 0.530 |
Why?
| | Thiazolidines | 1 | 2017 | 10 | 0.530 |
Why?
| | Alkaloids | 1 | 2017 | 32 | 0.530 |
Why?
| | Simulation Training | 1 | 2018 | 110 | 0.510 |
Why?
| | Albumins | 1 | 2017 | 116 | 0.510 |
Why?
| | Endoplasmic Reticulum | 2 | 2017 | 270 | 0.510 |
Why?
| | Amides | 1 | 2017 | 96 | 0.510 |
Why?
| | Carcinoma, Renal Cell | 1 | 2019 | 212 | 0.500 |
Why?
| | Enzyme Inhibitors | 2 | 2017 | 850 | 0.500 |
Why?
| | Protective Agents | 1 | 2016 | 42 | 0.500 |
Why?
| | Stress, Psychological | 1 | 2025 | 1124 | 0.500 |
Why?
| | Leptin | 2 | 2015 | 242 | 0.490 |
Why?
| | Benzodioxoles | 1 | 2017 | 116 | 0.480 |
Why?
| | Piperidines | 1 | 2017 | 215 | 0.460 |
Why?
| | Rats | 10 | 2019 | 5594 | 0.460 |
Why?
| | Oxidative Stress | 6 | 2019 | 1326 | 0.460 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 414 | 0.440 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 396 | 0.440 |
Why?
| | Kidney Diseases | 1 | 2018 | 407 | 0.420 |
Why?
| | Cell Survival | 4 | 2019 | 1129 | 0.400 |
Why?
| | Perception | 2 | 2025 | 368 | 0.380 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 621 | 0.350 |
Why?
| | Autophagy | 3 | 2018 | 286 | 0.340 |
Why?
| | Animals | 16 | 2019 | 37309 | 0.320 |
Why?
| | Curriculum | 4 | 2025 | 1005 | 0.300 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 2055 | 0.300 |
Why?
| | Apoptosis | 4 | 2019 | 2558 | 0.290 |
Why?
| | Superoxides | 1 | 2009 | 217 | 0.280 |
Why?
| | Superoxide Dismutase | 3 | 2009 | 353 | 0.280 |
Why?
| | Hypoglycemic Agents | 1 | 2017 | 1302 | 0.280 |
Why?
| | Antioxidants | 3 | 2019 | 593 | 0.270 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2161 | 0.270 |
Why?
| | Biomarkers | 2 | 2019 | 4111 | 0.260 |
Why?
| | Educational Measurement | 2 | 2025 | 292 | 0.240 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2018 | 211 | 0.240 |
Why?
| | Humans | 19 | 2025 | 138651 | 0.230 |
Why?
| | Cell Line | 3 | 2017 | 2874 | 0.230 |
Why?
| | Thinking | 1 | 2025 | 68 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2017 | 445 | 0.220 |
Why?
| | Faculty, Pharmacy | 1 | 2024 | 21 | 0.220 |
Why?
| | Obesity | 2 | 2015 | 2994 | 0.220 |
Why?
| | Schools, Pharmacy | 1 | 2024 | 49 | 0.220 |
Why?
| | Learning | 2 | 2025 | 418 | 0.210 |
Why?
| | Population Health | 1 | 2025 | 48 | 0.210 |
Why?
| | Pharmacy | 1 | 2024 | 34 | 0.210 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2023 | 55 | 0.200 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 97 | 0.200 |
Why?
| | Pharmaceutical Services | 1 | 2024 | 86 | 0.200 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 196 | 0.190 |
Why?
| | Oligonucleotides, Antisense | 1 | 2022 | 110 | 0.190 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2021 | 26 | 0.180 |
Why?
| | Sodium | 1 | 2021 | 197 | 0.170 |
Why?
| | Signal Transduction | 4 | 2019 | 5091 | 0.170 |
Why?
| | Male | 9 | 2025 | 68216 | 0.160 |
Why?
| | Adenosine Triphosphate | 2 | 2015 | 489 | 0.160 |
Why?
| | Streptozocin | 1 | 2019 | 23 | 0.160 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 5868 | 0.150 |
Why?
| | Qatar | 1 | 2018 | 1 | 0.150 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2019 | 193 | 0.140 |
Why?
| | Rats, Wistar | 1 | 2019 | 454 | 0.140 |
Why?
| | Receptor, Melanocortin, Type 4 | 2 | 2015 | 17 | 0.140 |
Why?
| | Cell-Derived Microparticles | 1 | 2019 | 72 | 0.140 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2838 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2024 | 443 | 0.140 |
Why?
| | Caspase 12 | 1 | 2017 | 2 | 0.130 |
Why?
| | Tunicamycin | 1 | 2017 | 13 | 0.130 |
Why?
| | Transcription Factor CHOP | 1 | 2017 | 34 | 0.130 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 949 | 0.130 |
Why?
| | Sorbitol | 1 | 2017 | 14 | 0.130 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2017 | 100 | 0.130 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 130 | 0.130 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 143 | 0.120 |
Why?
| | Cell Cycle | 1 | 2019 | 598 | 0.120 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2017 | 191 | 0.120 |
Why?
| | Glycation End Products, Advanced | 1 | 2017 | 83 | 0.120 |
Why?
| | Caspase 3 | 1 | 2017 | 250 | 0.120 |
Why?
| | Female | 5 | 2025 | 73913 | 0.120 |
Why?
| | Substrate Specificity | 1 | 2017 | 385 | 0.120 |
Why?
| | Catalytic Domain | 1 | 2017 | 228 | 0.120 |
Why?
| | Structure-Activity Relationship | 1 | 2017 | 569 | 0.120 |
Why?
| | Up-Regulation | 2 | 2017 | 851 | 0.120 |
Why?
| | Protein Carbonylation | 1 | 2015 | 55 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2045 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 323 | 0.110 |
Why?
| | Reperfusion Injury | 2 | 2008 | 287 | 0.110 |
Why?
| | Cell Movement | 1 | 2019 | 972 | 0.110 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 629 | 0.110 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 417 | 0.110 |
Why?
| | Internet | 1 | 2018 | 674 | 0.100 |
Why?
| | Triglycerides | 1 | 2015 | 515 | 0.100 |
Why?
| | Phosphorylation | 1 | 2017 | 1770 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2017 | 708 | 0.090 |
Why?
| | Oxygen Consumption | 1 | 2015 | 708 | 0.090 |
Why?
| | Cells, Cultured | 1 | 2019 | 4175 | 0.090 |
Why?
| | Cell Proliferation | 1 | 2019 | 2474 | 0.090 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 914 | 0.090 |
Why?
| | Epithelial Cells | 1 | 2017 | 1102 | 0.080 |
Why?
| | Melanocortins | 1 | 2010 | 2 | 0.080 |
Why?
| | Blood Glucose | 1 | 2019 | 2190 | 0.080 |
Why?
| | Electron Transport Complex III | 1 | 2009 | 19 | 0.080 |
Why?
| | Adult | 2 | 2025 | 38296 | 0.080 |
Why?
| | Sympathetic Nervous System | 1 | 2010 | 175 | 0.070 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2009 | 73 | 0.070 |
Why?
| | Blood Pressure | 1 | 2015 | 1734 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2857 | 0.070 |
Why?
| | Mice, Knockout | 1 | 2015 | 3038 | 0.070 |
Why?
| | Young Adult | 1 | 2025 | 13322 | 0.070 |
Why?
| | Transgenes | 1 | 2009 | 185 | 0.070 |
Why?
| | Metalloporphyrins | 2 | 2007 | 105 | 0.070 |
Why?
| | Organ Preservation | 1 | 2008 | 103 | 0.070 |
Why?
| | Cryopreservation | 1 | 2008 | 104 | 0.060 |
Why?
| | Transfection | 1 | 2009 | 942 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2009 | 2494 | 0.060 |
Why?
| | Neoplasms | 1 | 2020 | 2701 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2009 | 347 | 0.060 |
Why?
| | Mitochondrial Proteins | 1 | 2007 | 258 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 5812 | 0.050 |
Why?
| | Problem-Based Learning | 1 | 2025 | 95 | 0.050 |
Why?
| | Quinolines | 1 | 2004 | 151 | 0.050 |
Why?
| | Faculty | 1 | 2024 | 151 | 0.050 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2022 | 104 | 0.050 |
Why?
| | Teaching | 1 | 2025 | 230 | 0.050 |
Why?
| | Brain Ischemia | 1 | 2004 | 343 | 0.040 |
Why?
| | Mice | 2 | 2015 | 17848 | 0.040 |
Why?
| | Immunization | 1 | 2022 | 405 | 0.040 |
Why?
| | Nucleic Acids | 1 | 2020 | 70 | 0.040 |
Why?
| | Nanostructures | 1 | 2020 | 109 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2022 | 359 | 0.040 |
Why?
| | Rats, Inbred F344 | 2 | 2008 | 267 | 0.030 |
Why?
| | RNA | 1 | 2020 | 928 | 0.030 |
Why?
| | Pro-Opiomelanocortin | 1 | 2010 | 20 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1225 | 0.020 |
Why?
| | Adipocytes | 1 | 2010 | 227 | 0.020 |
Why?
| | Ischemic Preconditioning | 1 | 2008 | 48 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2008 | 159 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 112 | 0.020 |
Why?
| | Probability | 1 | 2008 | 309 | 0.020 |
Why?
| | Random Allocation | 1 | 2008 | 364 | 0.020 |
Why?
| | Body Weight | 1 | 2010 | 990 | 0.010 |
Why?
| | Adipose Tissue | 1 | 2010 | 643 | 0.010 |
Why?
| | Blotting, Western | 1 | 2008 | 1229 | 0.010 |
Why?
| | Graft Survival | 1 | 2008 | 527 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2008 | 1320 | 0.010 |
Why?
| | Isoquinolines | 1 | 2004 | 46 | 0.010 |
Why?
| | Cerebral Arterial Diseases | 1 | 2004 | 49 | 0.010 |
Why?
| | Graft Rejection | 1 | 2008 | 577 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2008 | 1732 | 0.010 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2004 | 116 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1958 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1815 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 1048 | 0.010 |
Why?
| | Kidney Transplantation | 1 | 2008 | 703 | 0.010 |
Why?
| | Hypertension | 1 | 2010 | 1253 | 0.010 |
Why?
| | Neurons | 1 | 2010 | 1603 | 0.010 |
Why?
| | Proteomics | 1 | 2007 | 1113 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2008 | 4333 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 10398 | 0.010 |
Why?
|
|
Munusamy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|